Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levodopa Reduction vs Non-Reduction Post-DBS in PD
NCT05901350Completed
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Jun 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of levodopa in Parkinson's disease (PD) (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Visual Impairment in Parkinson's Disease Questionnaire at 12 months. Started Jun 2019; status: completed.
02
Drugs
levodopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05901350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05901350.